Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Long-term follow-up of clinical and optical quality outcomes of LASIK for the correction of high levels of myopia

Poster Details

First Author: A.Vega-Estrada SPAIN

Co Author(s):    J. Alio   P. Sanz Diez                 

Abstract Details

Purpose:

To evaluate the long-term outcomes of laser in situ keratomileusis (LASIK) for the correction of high myopia using a 500 Hz repetition rate excimer laser and optimized aspherical profile.

Setting:

Vissum, Alicante, Spain.

Methods:

Retrospective consecutive noncomparative study evaluating 70 eyes of 40 patients with ages ranging from 24 to 56 years (mean age of 35.67±8.44 years) that underwent uneventful primary LASIK surgery. LASIK procedures were performed using the Amaris excimer laser (Schwind Eye-Tech-Solutions, Kleinostheim, Germany). All treatments performed for patients included in the current series were based on optimized aspherical ablation profile. Visual, refractive, topographic and corneal aberrometric changes were evaluated. 70 cases were followed during 3 years and 34 during 5 years.

Results:

A significant improvement of about 15 LogMAR lines was observed in uncorrected vision at 5 years after surgery (p<0.01). This improvement was consistent with a significant reduction of spherical equivalent that came from preoperative -7.79 ± 1.38 diopters (D) to 3 years postoperative -0.24 ± 0.54 D (p<0.01). Pearson correlation showed that the amount of high order aberrations at 3 months postoperativeley was significantly correlated with the changes in the keratometry throughout the 5 years (deltaK) (R2 0.242 p= 0.05).

Conclusions:

LASIK for the correction of high levels of myopia using optimized aspherical profiles and the Amaris excimer laser is a safe, effective and predictable procedure with stable results after long period of follow up.

Financial Disclosure:

None

Back to Poster listing